<b>Colorectal cancer (CRC) is now cited as the third most common cancer worldwide.  Diagnosis currently requires invasive sampling and typically results in late stage detection; thus rapid, non-invasive detection provided by drop coating deposition Raman spectroscopy (DCDRS) of human blood plasma is preferred. Raman spectroscopy has assisted in enhancing cancer detection for decades, but only one application of DCDRS for cancer detection has been developed since its discovery in 2003. DCDRS has previously detected differences between fifteen patients with stage III or IV CRC with a mean age of 54 and twenty-one healthy patients with a mean age of 38; however, it has not yet been determined whether DCDRS is capable of differentiating between patients with various cancers. Herein, we have examined the blood plasma of patients with prostate cancer, lung cancer, renal cell carcinoma, and rheumatoid arthritis using DCDRS. Raman spectra were collected from 180 blood plasma samples using a Renishaw InVia Raman spectrometer.  Spectra were analyzed by principal components analysis (PCA) and multivariate curve resolution–alternating least squares (MCR-ALS) to identify spectral features that varied across the dataset. The results  complement evidence suggesting DCDRS will be an effective colon cancer detection tool as well as a viable detection method for other pathologies.  </b>

Harnessing drop coat deposition Raman spectroscopy (DCDRS) of blood plasma for cancer diagnosis: Colon cancer, lung cancer, renal cell carcinoma, rheumatoid arthritis

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.